Zai Lab Ltd
ZLABHealthcare|Biotechnology|China
$20.49
+0.52 (+2.60%)
Tangible Book
$5.25
Upcoming Data Readouts (8)
Mar 2027
Est. completion
P3Thyroid Eye Disease (TED)
A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease
NCT07211776n=99
May 2027
Est. completion
Aug 2027
Est. completion
Dec 2027
Est. completion
P1Atopic Dermatitis (AD)
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
NCT07235384n=84
Feb 2028
Est. completion
P1P2Locally Advanced Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116n=500
Jun 2028
Est. completion
P3Small-cell Lung Cancer
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146n=480
Aug 2028
Est. completion
P1Solid Tumors
Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors
NCT07374848n=180
Dec 2028
Est. completion
P2P3Primary Membranous Nephropathy
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275n=176
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Mar 2026
P3
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
NCT06140836